PL BioScience Launches World's Only Patented Gamma-irradiated Human Platelet Lysate
AACHEN, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced the launch of ELAREM™ Ultimate-FD PLUS, the only gamma-irradiated, GMP-grade Human Platelet Lysate produced in Germany using a globally patented process. With the increasing demand for safe, xeno-free, ethically sourced cell culture supplements in cell therapy, regenerative medicine, and biopharmaceutical manufacturing, ELAREM™ Ultimate-FD PLUS answers a critical industry need: a virus-inactivated, animal-free, and EU-manufactured alternative that meets the highest quality standards.
'We are thrilled to bring the only gamma-irradiated Human Platelet Lysate produced in Europe to the dynamic field of cell and gene therapy,' said Dr. Hatim Hemeda, Chief Executive Officer of PL BioScience. 'This product isn't just a milestone for Europe – it's a globally unique offering. With comprehensive patent protection and fully EU-based production, ELAREM™ Ultimate-FD PLUS ensures a stable supply chain and offers global manufacturers a high-quality, regulatory-ready solution that meets the highest international standards.'
Cell culture supplements are essential for growing cells in the laboratory. They play a critical role in the development and manufacturing of advanced therapies like cell and gene therapies. Traditionally, these supplements often contain components derived from other species, such as fetal bovine serum (FBS). These animal-derived products carry potential safety risks, for example bacterial or viral contamination, and pose ethical concerns. HPL offers a fully human-derived, xeno-free alternative that is safe, consistent, and sustainable.
ELAREM™ Ultimate-FD PLUS takes this one step further. Through a proprietary gamma-irradiation process, the product undergoes viral inactivation to add an extra layer of safety and regulatory assurance. The gamma-irradiated, xeno-free, fibrinogen-depleted, and anticoagulant-free product complies with the relevant GMP (Good Manufacturing Practice) guidelines. This makes it especially suitable for cell manufacturing applications where viral reduction is critical, such as potential use in clinical trials.
About Human Platelet Lysate:
Human Platelet Lysate (HPL) is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. It is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable and resource-efficient alternative to traditional cell culture supplements.
In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices.
ELAREM™, PL BioScience's line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients.
About PL BioScience:
Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HPL), offering a complete portfolio of HPL products tailored for various use cases. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. With ELAREM™ Ultimate-FD PLUS, PL BioScience produces the only globally patented gamma-irradiated HPL product. For more information on PL BioScience and the ELAREM™ product offerings, visit: https://www.pl-bioscience.com/
Contact:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
[email protected]
Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0
US: Catherine Featherston
+1-203-444-4393
E-Mail: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
DigitalOcean and AMD Collaborate to Advance AI Using Cloud-Based GPUs
NEW YORK--(BUSINESS WIRE)-- DigitalOcean Holdings, Inc. (NYSE: DOCN), the simplest scalable cloud for digital native enterprises, today announced a collaboration with AMD that provides DigitalOcean customers with access to AMD Instinct™ GPUs as DigitalOcean GPU Droplets to power their AI workloads starting with the AMD MI300X GPUs. Later this year, DigitalOcean will offer AMD Instinct™ MI325X GPUs, further expanding access to powerful and affordable GPU models. AMD Instinct™ MI325X GPU accelerators set new AI performance standards, delivering incredible performance and efficiency for training and inference. AMD Instinct MI300X GPUs deliver leadership performance for accelerated high-performance computing (HPC) applications and the newly exploding demands of generative AI. With the AMD ROCm™ software platform, customers can develop powerful HPC and AI production-ready systems faster than ever before. Its large memory capacity allows it to hold models with hundreds of billions of parameters entirely in memory, reducing the need for model splitting across multiple GPUs. By combining powerful AMD AI compute engines and DigitalOcean's cloud technologies, the collaboration aims to empower the massive community of digital native enterprises to integrate AI into their applications and support the most demanding AI workloads at scale. These next-generation GPUs have already been available in bare metal configurations for customers seeking increased control and computing power. These GPUs are now also available as GPU Droplets or as DigitalOcean Kubernetes worker nodes. The GPU Droplets are available both as single and eight GPU configurations, allowing customers to optimize costs for their specific use cases. Accessing these GPU Droplets through DigitalOcean offers several key benefits, including competitive pricing at $1.99/GPU per hour, a simple setup process, and enterprise-grade SLAs. While other cloud providers require multiple steps and deep technical knowledge to configure security, storage, and network requirements, DigitalOcean's GPU Droplets can be set up with just a few clicks. In addition to these new GPUs, customers will also have access to AMD Developer Cloud, a new platform powered by DigitalOcean that is purpose-built for rapid, high-performance AI development. Customers will have access to a fully managed environment that provides instant access to AMD Instinct MI300X GPUs—with zero hardware investment or local setup required. Whether fine-tuning LLMs, benchmarking inference performance, or building a scalable inference stack, the AMD Developer Cloud provides the tools and flexibility to get started instantly—and grow without limits. 'DigitalOcean's collaboration with AMD is another proof point to make AI easily accessible to our customers,' said Bratin Saha, Chief Product & Technology Officer at DigitalOcean. 'With access to AMD GPUs, DigitalOcean customers have an extensive portfolio of GPUs with the flexibility of the computing configuration that best suits their requirements.' "At AMD, we are proud to work with DigitalOcean to provide developers with cutting-edge solutions for developer enablement and demanding workloads that require large amounts of memory,' said Negin Oliver, corporate vice president of business development, Data Center GPU Business, at AMD. 'Together, AMD and DigitalOcean are committed to providing the critical innovative technologies required to support the evolving needs of growing tech businesses.' To access AMD Instinct GPUs with DigitalOcean, visit the DigitalOcean website. DigitalOcean is the simplest scalable cloud platform that democratizes cloud and AI for digital native enterprises around the world. Our mission is to simplify cloud computing and AI to allow builders to spend more time creating software that changes the world. More than 600,000 customers trust DigitalOcean to deliver the cloud, AI, and ML infrastructure they need to build and scale their organizations. To learn more about DigitalOcean, visit
Yahoo
4 hours ago
- Yahoo
Implantable Remote Patient Monitoring Devices Market to Grow 21.7% CAGR by 2029
"Innovation-Driven and Knowledge-Intensive: Implantable Remote Patient Monitoring Devices Seek Flexible, Integrated Solutions Amid Accelerating Market Timelines and Rising Competition" Boston, June 12, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the 'Global Implantable Remote Patient Monitoring Devices Market' is expected to grow from $7.6 billion in 2024 to $20.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 21.7% from 2024 to 2029. The report on the implantable remote patient monitoring (IRPM) device market analyzes market shares by product, indication and end users. It segments the market into device types, such as cardiovascular, brain, gastrointestinal, hematological, respiratory, and musculoskeletal monitoring devices. Indication consists of cardiovascular diseases, brain disorders, and diabetes End users include hospitals, clinics, and home healthcare settings. Additionally, it offers a study of the competitive landscape, regional analysis, consumer insights, and a supply chain analysis, helping stakeholders make informed decisions and identify strategic opportunities. This report is particularly relevant today because implantable remote patient monitoring (IRPM) devices are transforming healthcare by enhancing patient outcomes, lowering healthcare costs, and increasing accessibility. These devices facilitate continuous monitoring of chronic conditions, enabling real-time data collection and analysis, which can lead to early detection of complications and more timely interventions. The factors driving the market's growth include: Chronic Diseases and the Aging Population: The rise in chronic diseases and the global aging population increase the need for continuous health monitoring. Implantable devices help manage these conditions more effectively, reducing hospital visits and improving patient outcomes. Demand for mHealth Applications: mHealth apps are gaining in popularity for their convenience and real-time health data. They enhance implantable devices by providing comprehensive health data, driven by the widespread use of smartphones and rising awareness of the benefits of digital health. Improved Wireless Technologies: Advances in wireless tech, such as 5G, improve the reliability and efficiency of remote patient monitoring. These technologies enable faster data transmission and more stable connections, which are crucial for real-time health monitoring. Request a sample copy of the global market for implantable remote patient monitoring (IRPM) devices report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $6.5 billion Market size forecast $20.3 billion Growth rate CAGR of 21.7% from 2024 to 2029 Segments covered By product, disease indication, end user, and region Regions covered North America, Europe, Asia-Pacific, and the Rest of World (RoW) Market drivers Increasing prevalence of chronic diseases due to an aging population. Growing demand for mHealth applications. Improved wireless communication technologies. Interesting facts: Reducing Hospital Readmissions: Implantable RPM devices can decrease hospital readmissions by up to 30%, which is crucial for managing chronic conditions like heart failure. Innovative Power Sources and AI Integration: Some implantable devices are powered by the human body, eliminating the need for external batteries. Additionally, integrating artificial intelligence (AI) enhances their predictive capabilities, allowing real-time adjustments to patient care. The report addresses the following questions: What is the projected size and growth rate of the global market for implantable remote patient monitoring devices? The global market for implantable remote patient monitoring devices was valued at $6.5 billion in 2023 and is expected to reach $20.3 billion by the end of 2029, at a CAGR of 21.7% from 2024 to 2029. What are the key factors driving the growth of the market? These include the increasing prevalence of chronic diseases due to an aging population, growing demand for mHealth applications, and improved wireless communication technologies. What market segments does the report cover? The global market for implantable remote patient monitoring devices is segmented by product, indication, end user and region. Which indication segment will enjoy market dominance through the forecast period? The cardiovascular diseases segment will have that position. Which region has the largest share of the global market for implantable remote patient monitoring devices? North America holds the largest share of the market. Leading Companies Include: ABBOTT AVERTIX MEDICAL INC. BIOTRONIK BOSTON SCIENTIFIC CORP. CARDIAC RMS DEXCOM INC. EBR SYSTEMS INC. ENDOTRONIX INC. INJECTSENSE INC. IMPULSE DYNAMICS MEDICO S.R.L. MEDTRONIC PROFUSA INC. QURA LLC. VITALCONNECT Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Purchase a copy of the report directly from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
4 hours ago
- Hamilton Spectator
First of Its Kind in the Region: KFSHRC Successfully Performs Endoscopic Sleeve Gastroplasty on Kidney Transplant Patient
RIYADH, Saudi Arabia, June 12, 2025 (GLOBE NEWSWIRE) — In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully performed an endoscopic sleeve gastroplasty (ESG) on a patient who had previously undergone a kidney transplant, a case that requires meticulous management of immunosuppressive medications and the prevention of any complications that could jeopardize the transplanted organ. This procedure marks a significant advancement in providing safe treatment solutions for transplant recipients, to improve their graft survival and quality of life. Known as Endoscopic Sleeve Gastroplasty (ESG), the procedure differs from surgical sleeve gastrectomy in that it requires no abdominal incisions, which is important for transplant patients. Instead, it uses an endoscope inserted through the mouth to suture the stomach internally, effectively reducing its volume and enabling the patient to lose weight and improve overall health. The procedure aimed to address obesity and metabolic, which are among the leading factors that can negatively impact the health of a transplanted kidney, increase cardiovascular risk, and reduce long-term patient outcomes. The procedure was performed by a multidisciplinary team of medical experts, led by Dr. Ehab Abufarhaneh, Consultant in Adult Transplant Gastroenterology and Hepatology. The team included gastroenterologists, an upper GI surgeon, transplant surgeons, transplant Nephrology, and transplant anaesthesiologists, all supported by highly trained nursing staff to ensure the highest level of safety, with particular focus on managing the patient's immunosuppressive regimen—critical to preserving kidney graft function. This achievement underscores the pivotal role of KFSHRC's Organ Transplant Centre of Excellence as a leading medical environment capable of delivering precise interventions for complex transplant cases. By adopting innovative techniques tailored to the unique needs of transplant patients and developing treatment protocols that address post-transplant challenges, the centre reinforces its position as a regional referral hub for cases beyond the scope of conventional treatment pathways. The success of this procedure further exemplifies KFSHRC's ongoing commitment to delivering advanced, patient-centred healthcare and fulfilling its vision of being the optimal choice for patients supported by an integrated ecosystem of education, research, and clinical excellence that aligns with the ambitions of Saudi Arabia's health sector. It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at mediacoverage@ . A photo accompanying this announcement is available at
